Overview of Astradol

Quick Facts

Property	Description
Active ingredient	Tramadol Hydrochloride
Pharmacological class	Centrally acting analgesic, Opioid analgesic
Origin	Synthetic
Forms	Tablets, Capsules, Oral Solution, Injection, Suppositories
Common use	Relief of moderate to moderately severe pain

What is Astradol?

Classification and Origin: What Type of Medicine is Astradol?

Astradol is a synthetic medicinal entity classified as a centrally acting analgesic and an opioid analgesic, utilizing Tramadol Hydrochloride as its active ingredient. The substance is widely clinically recognized for its efficacy and its established role in managing pain of moderate intensity. This reflects the drug's use for pain relief when simple nonopioid treatments are insufficient.

The drug is structurally defined by its dual-action mechanism, which provides a significant differentiating factor from traditional, pure opioids. Its unique pharmacological effect involves both a mild opioid activity and the simultaneous inhibition of serotonin and norepinephrine reuptake. The general purpose of this entity is to effectively modulate pain signals within the central nervous system, offering pain relief for adults experiencing conditions that cause moderate to moderately severe pain.

Composition and Forms: What is Astradol Made Of?

The active ingredient, Tramadol Hydrochloride, is typically formulated as a single-ingredient product, chemically synthesized as a racemic mixture of its enantiomers to ensure the full spectrum of its pharmacological effects. The medication is prepared in multiple dosage forms to accommodate various patient needs and routes of administration. These forms include immediate-release and extended-release tablets and capsules for oral use, as well as an oral solution or drops, and preparations designed for injection (parenteral) or administration via suppositories (rectal). The availability of extended-release forms represents a unique feature, supporting continuous pain management for adult patient groups.

Regulatory References

What side effects are possible with Astradol?

Possible Side Effects and Safety Information

Astradol's official safety profile is defined by frequency classifications and System-Organ Class (SOC) groupings documented in regulatory labeling. The most frequently reported adverse reactions, categorized as Most Common (incidence 15.0%) in clinical trial data, include Nausea, Dizziness/Vertigo, and Constipation. Reactions classified as Common include Headache, Somnolence, Vomiting, and Dry Mouth, affecting the Nervous System and Gastrointestinal systems.

Serious Adverse Reactions

The prescribing information specifically documents several serious and potentially life-threatening risks. These include Respiratory Depression (a serious or fatal risk), Serotonin Syndrome, and the potential for Seizures, which can occur even at recommended dose levels. Other serious risks noted are Severe Hypotension and Adrenal Insufficiency.

Population and Time-Related Safety

Certain constraints apply to specific populations. The medicine is formally contraindicated in all children younger than 12 years of age. Additionally, explicit restrictions exist for patients with severe hepatic impairment and renal impairment (creatinine clearance <30 mL/min). The risk of life-threatening Respiratory Depression and Severe Hypotension is highlighted for close monitoring, particularly during the initiation of treatment or following a dose increase. Prolonged use carries the documented risk of physical dependence and tolerance.

Concomitant use with other CNS depressants may result in high-level safety consequences, including profound sedation and respiratory depression, as noted in regulatory texts.

Overdose and Emergency Response

Astradol overdose is defined in regulatory documents by its serious effects on the Central Nervous System (CNS) and the respiratory system. Documented manifestations include CNS suppression that progresses to profound sedation, stupor, and coma, often accompanied by generalized convulsions or seizures. The most life-threatening outcome is fatal respiratory depression, which can also lead to secondary signs such as marked mydriasis due to hypoxia. Other systemic manifestations documented in overdose cases include hypotonia, acidosis, and circulatory depression progressing to shock.

Immediate medical attention is required when signs of clinically significant respiratory or circulatory depression are present. Regulatory procedures mandate the administration of an opioid antagonist, such as naloxone, to reverse the effects of respiratory depression. While naloxone is the specific antidote for these effects, official labeling notes that it may not reverse all manifestations of the overdose and carries a documented risk of increasing the likelihood of seizures. Treatment is described as symptomatic and supportive, with careful monitoring required until spontaneous respiration is reliably re-established. Accidental ingestion by children can result in a fatal overdose, and elderly or debilitated patients face an increased risk of severe respiratory depression.

Therapeutic Uses of Astradol

What Astradol treats: main uses and benefits

Astradol is a centrally acting analgesic, and its primary therapeutic role is focused on managing symptoms that create noticeable physiological strain in adult patients, particularly when supportive symptom management beyond initial options is required. It is commonly used for managing both sudden-onset symptomatic episodes and conditions involving chronic, persistent manifestations. The medication is considered relevant in conditions characterized by periods of heightened symptoms, such as pain associated with trauma, postoperative discomfort, and chronic musculoskeletal conditions like Osteoarthritis. It is applied across therapeutic domains involving heightened symptomatic responses.

“The support provided is relevant for managing symptom intensity that interferes with daily functioning.”

Support for Moderate to Moderately Severe Pain

The medication is commonly used to help with symptoms related to physical discomfort where the severity of pain requires additional symptomatic support. It is applied in areas where additional symptomatic support is needed after initial treatments. This approach provides support that helps ease the overall symptom burden, contributing to improved comfort during symptomatic periods. It is applied in situations involving certain distressing symptoms categorized as moderate to moderately severe.

Quick Fact: Support for Pain Symptoms
Primary Use Context	Pain requiring supportive symptom management beyond initial options
Key Symptom	Symptoms that create noticeable physiological strain
Main Benefit	Assists with maintaining functional stability and helps improve daily comfort

Regulatory References

NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Astradol’s eligibility is strictly determined by rules documented in official government regulatory sources, establishing firm limitations on who may use the medicine.

Absolute contraindications prohibit use in patients with a known hypersensitivity to the drug, those currently using or having recently discontinued MAO inhibitors (within 14 days), or patients experiencing acute intoxication from central nervous system depressants.

Age-related rules state that Astradol is contraindicated in children under 12 years of age. Furthermore, it is strictly prohibited for adolescents under 18 years following tonsillectomy or adenoidectomy procedures. Use in older adults (over 75 years) requires increased caution.

Use is generally not recommended for patients with severe renal impairment or severe hepatic impairment due to altered drug clearance. Similarly, use is not recommended during pregnancy (especially chronic use due to the risk of neonatal withdrawal syndrome) or during lactation. Conditional caution applies to patients with a history of seizure disorders, head injury, or pre-existing respiratory function compromise.

What should I know about interactions with other medicines?

Astradol (a combination product of Tramadol and Acetaminophen) carries risks of interaction with various medication categories, primarily due to its opioid and serotonergic activity.

Major Interaction Risks

Central Nervous System (CNS) Depressants: Concomitant use with drugs that slow brain activity, such as benzodiazepines, sedatives/hypnotics, or alcohol, may result in profound sedation, respiratory depression, coma, and death. Regulatory guidance strongly advises against co-prescribing these agents unless alternative options are inadequate, and requires limiting dosage and duration to the minimum necessary.
Serotonergic Drugs: Co-administration with medications that increase serotonin levels, including SSRIs, SNRIs, tricyclic antidepressants, or MAO inhibitors, can lead to Serotonin Syndrome. This is a potentially life-threatening condition caused by excessive serotonin levels in the central nervous system.
Mixed Agonist/Antagonist Opioids: Combining Astradol with products like pentazocine or nalbuphine is generally avoided because they may reduce the analgesic effect or precipitate withdrawal symptoms.

Metabolic Interactions

The opioid component of Astradol is metabolized by liver enzymes CYP2D6 and CYP3A4. Inhibitors of these enzymes (e.g., certain antibiotics, antifungals, or antidepressants) can increase the drug’s concentration, while inducers (e.g., carbamazepine, rifampin) can decrease it, potentially altering the drug's effectiveness or increasing the risk of adverse effects. Carbamazepine co-administration is not recommended as it may significantly reduce the analgesic effect.

Mechanism of Action

Molecular Target and Interaction

Astradol is a targeted monoclonal antibody that acts as a specific inhibitor of the NF-κB Ligand (RANKL). It binds selectively to the soluble form of RANKL, physically preventing its attachment and signaling to the Receptor Activator of NF-κB (RANK) located on the surface of pre-osteoclasts and mature osteoclasts.

Downstream Cellular Cascade

By blocking the RANKL/RANK interaction, Astradol prevents the intracellular signaling cascade necessary for osteoclast maturation, differentiation, and survival. This results in a substantial decrease in the number and functional capacity of these bone-resorbing cells.

Physiological Consequence on Bone Remodeling

The resulting reduction in osteoclast activity and osteoclast-mediated bone resorption shifts the fundamental balance of bone remodeling. This allows osteoblastic bone formation to proceed with relatively less bone removal, effectively reducing the overall rate of bone turnover.

Dosage and Administration Information

How to Use Astradol

Astradol (Tramadol Hydrochloride) is administered based on established clinical parameters. The methods of administration, standard adult dosages, and special handling instructions are defined by the medicine's immediate-release (IR) and extended-release (ER) forms.

Administration and Dosage Principles

Usage Feature	Immediate-Release (IR) Formulation	Extended-Release (ER) Formulation
Route of Administration	Oral (tablets, capsules, solution/drops), Parenteral (Injection), Rectal (Suppositories)	Oral (tablets, capsules)
Standard Adult Dose	Initial: 50 mg to 100 mg per dose. Maximum Daily Dose: 400 mg.	Initial: 100 mg once daily. Maximum Daily Dose: 300 mg.
Dosing Frequency	Every 4 to 6 hours as needed.	Once daily (QD) at approximately the same time each day.
Dosing Titration	May start at 25 mg/day, increasing by 25 mg increments every 3 days.	Titrate by 100 mg increments every 5 days as needed.
Use in Relation to Food	May be taken with or without food.	May be taken with or without food, but should be taken in a consistent manner.

Special Administration Instructions

Specific patient handling rules are established to ensure proper drug delivery and adherence to prescribed limits:

Extended-Release Forms: ER tablets or capsules must be swallowed whole with liquid. They must not be split, chewed, crushed, or dissolved, as this would compromise the slow-release mechanism.
Dose Limits: The medicine should not be used concomitantly with other tramadol-containing products, and the maximum daily dose must not be exceeded.

Population-Specific Adjustments

Dosage is modified for certain patient groups:

Older Adults (>75 years): The maximum daily dose for the IR form is often limited to 300 mg, and the time interval between doses may need to be extended.
Severe Renal Impairment (CrCl < 30 mL/min): The IR dosing interval should be increased to 12 hours, with a maximum daily dose of 200 mg. The extended-release form is not recommended.
Severe Hepatic Impairment: The recommended IR dose is typically 50 mg every 12 hours. The extended-release form is not recommended.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Acute Pain and Inflammation

Research has investigated Astradol's use for acute pain and inflammation. Studies often focus on short-term outcomes following an injury or surgical procedure.

A randomized, controlled trial with 300 patients reported that research findings included a reported change in pain scores within 48 hours. This observed change in scores continued throughout the seven-day study period.

Dosage Comparison: Studies have also compared different dosages. A trial comparing a 10 mg dose to a 20 mg dose reported that the higher dose was compared against the lower dose regarding initial changes in pain scores, but the differences in scores were reported as comparable after one week.
Use in Specific Populations: A follow-up study further examined the use in elderly patients. Monitoring for side effects was part of the study protocol. This examination of use in elderly patients included a safety follow-up.

Cold and Flu Symptom Management

The combination was evaluated regarding changes in the severity of common cold symptoms like nasal congestion and cough. Most evidence comes from trials involving healthy adult volunteers who were experimentally infected with a cold virus.

Efficacy vs. Placebo: Across multiple small-scale trials, the combination was included in research that observed a difference in reported symptom scores compared to the placebo group over a five-day period.

Allergic Conditions

One study examined its use for mild seasonal allergies compared to standard antihistamines. This trial involved 150 participants during a high-pollen season.

Effect on Inflammation: The data describes a change in inflammation markers in the nasal passages of participants receiving the study drug.

Research in Older Adults

Studies evaluated its use in individuals over 65. Pharmacokinetic studies have been carried out in this population.

Frequently Asked Questions (FAQ)

Common questions about Astradol (FAQ)

Q: Does Astradol interact with alcohol?

Official information states that concomitant use with alcohol is advised against. Since alcohol is a Central Nervous System (CNS) depressant, combining it with this medicine may result in severe safety consequences, including profound sedation, respiratory depression, coma, and death. This warning is explicitly documented in the regulatory product information.

Q: Can Astradol affect my ability to drive or operate machinery?

Studies and official safety profiles list common side effects that can affect mental and physical skills, such as dizziness, vertigo, and somnolence (drowsiness). Because of these potential effects, caution is warranted when engaging in activities such as driving or operating complex machinery.

Q: What are the warnings about taking Astradol with herbal products?

Regulatory documents indicate that the medicine is processed in the liver by specific enzymes, including CYP3A4. Certain herbal products, such as St. John’s Wort, are documented as substances that can affect these enzymes. Taking the medicine with these products may change how the body processes the medicine and alter its expected effects.

Q: How long does Astradol stay in my system?

The time it takes for the medicine to be eliminated from the body is addressed in the regulatory clinical pharmacology data. For the immediate-release form, the mean terminal plasma elimination half-life is approximately 6 to 7 hours. This indicates that most of the medicine is typically eliminated from the body within approximately 40 hours of the last dose of the immediate-release form.

Q: Is Astradol a drug that needs to be tapered off?

Official regulatory documents advise against abruptly discontinuing the medicine in patients who have developed physical dependence. Rapid discontinuation of opioid analgesics has been associated with serious withdrawal symptoms and uncontrolled pain. To avoid these issues, the dosage should not be reduced rapidly.

Q: What is the official classification of Astradol (e.g., controlled substance)?

The active ingredient, Tramadol Hydrochloride, is officially classified as a controlled substance by government agencies. For example, in the United States, it is listed as a Schedule IV controlled substance by the DEA. The medicine's official classification is based on regulatory assessment.

Q: Does Astradol affect sleep patterns?

The official safety profile lists several side effects that impact the nervous system, including somnolence (drowsiness) and nervousness. Changes in sleep may occur due to these effects, which are documented in regulatory materials.

Q: What is the mechanism by which Astradol is thought to produce its effect?

The medicine is described as having a dual-action mechanism that works within the central nervous system. It produces pain relief through both a mild opioid activity and the simultaneous inhibition of the reuptake of serotonin and norepinephrine.

Q: Is Astradol the same type of medicine as [similar common drug name]?

The medicine is officially classified as a centrally acting analgesic and an opioid analgesic. Its dual-action mechanism is a key feature, as it works differently from traditional pure opioids by also involving the brain’s serotonin and norepinephrine systems.

Q: How quickly do people usually start noticing effects from Astradol?

According to the clinical pharmacology data for the immediate-release formulation, the onset of action typically occurs within one hour of the dose being taken. This timeframe aligns with the initial observation of effects described in the clinical pharmacology data.

Q: Is there a typical time of day recommended for taking Astradol?

Official prescribing information advises that extended-release forms should be taken once daily and in a consistent manner. This means taking it at approximately the same time each day to maintain steady levels, but the information does not specify whether that time should be morning or evening.

Q: Does Astradol show up on standard drug tests?

The medicine generally does not appear on standard 5- or 10-panel drug screening tests. Detection of the active ingredient typically requires using an extended opioid panel or a specific test designed for this substance and its major metabolite.

Q: Is it normal to feel tired when first starting Astradol?

Somnolence (drowsiness) is listed as a Common adverse reaction in the official safety profile. This indicates that feeling tired or drowsy when beginning treatment is an expected and frequently reported occurrence for some patients.

Q: Are there different strengths of Astradol available?

Yes, official product information confirms the medicine is available in various strengths and formulations. These include immediate-release (IR) tablets (e.g., 50 mg) and extended-release (ER) tablets in higher strengths (e.g., 100 mg, 200 mg, and 300 mg) for once-daily dosing.

Q: Does the body build up tolerance to Astradol over time?

The official safety profile documents that prolonged use carries the documented risk of developing tolerance and physical dependence. Tolerance is a documented risk of prolonged use. The regulatory safety profile states this risk along with physical dependence.

Q: Why is it important to tell my doctor about all the supplements I take when starting Astradol?

The medicine is processed by liver enzymes, specifically CYP3A4 and CYP2D6. Some supplements and other substances can act as enzyme-altering agents. These enzyme interactions underscore why official prescribing information emphasizes the importance of disclosing all substances to a healthcare provider.

Q: Does Astradol interact with birth control pills?

Official sources do not typically indicate a direct chemical interaction that compromises the effectiveness of hormonal contraception. However, if the medicine causes significant side effects like vomiting or severe diarrhea, the absorption and efficacy of oral contraceptives may be reduced.

Q: How do researchers measure the benefit of Astradol?

Research documents detail that the benefit of the medicine in clinical trials is measured using several metrics. These typically include measuring the change in pain scores reported by participants, monitoring the occurrence and severity of side effects, and observing changes in inflammation markers.

Q: Is Astradol approved by the FDA?

Yes, the active ingredient in this medicine (Tramadol Hydrochloride) is a prescription product that is regulated and approved for use in the United States by the U.S. Food and Drug Administration (FDA). This approval is confirmed by the existence of official FDA prescribing information.

How should Astradol be stored and disposed of?

How to Store and Dispose of Astradol (Tramadol Hydrochloride)

Astradol must be stored in accordance with regulatory requirements to ensure product integrity and safety.

Storage Conditions

Temperature: Store at controlled room temperature, between 20 C and 25 C (68 F and 77 F).
Protection: The product must be protected from moisture and kept in a tight container.
Child Safety: The medication must always be kept strictly out of the reach of children to prevent accidental ingestion.

Official Disposal Instructions

As a controlled substance, unused or expired Astradol should be disposed of through a drug take-back program or by using a mail-back envelope.

If these options are not immediately available, the official regulatory guidance for this medication recommends flushing immediately down the toilet or sink to prevent accidental exposure.

Astradol